Literature DB >> 17392392

Selective toxicity of aristolochic acids I and II.

Shinya Shibutani1, Huan Dong, Naomi Suzuki, Shiro Ueda, Frederick Miller, Arthur P Grollman.   

Abstract

Ingestion of herbal remedies containing aristolochic acids (AAs) is associated with the development of a syndrome, designated aristolochic acid nephropathy (AAN), which is characterized by chronic renal failure, tubulointerstitial fibrosis, and urothelial cancer. To distinguish the component(s) of AA responsible for these varied toxic effects, we administered 2.5 mg/kg/day of AA-I or AA-II for 9 days, either i.p. or p.o., to male C3H/He mice. Tissues were then collected and subjected to biochemical and histopathologic examination. Genotoxicity was assessed by determining quantitatively the level of aristolactam-DNA adducts in various tissues using (32)P-postlabeling/polyacrylamide gel electrophoresis and an internal standard. In the primary target tissues, represented by the renal cortex, medulla, and bladder, we found similar levels of DNA adducts derived from AA-I and AA-II. However, in nontarget tissues, the liver, stomach, intestine, and lung, the levels of aristolactam-DNA adducts derived from AA-I were significantly higher than those derived from AA-II. Histopathologic analysis revealed tubular cell necrosis and interstitial fibrosis in the renal cortex of AA-I-treated mice but only minimal changes in the renal cortex of mice treated with AA-II. We conclude that AA-I and AA-II have similar genotoxic and carcinogenic potential, and, although both compounds are cytotoxic, AA-I is solely responsible for the nephrotoxicity associated with AAN.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392392     DOI: 10.1124/dmd.107.014688

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  49 in total

1.  Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.

Authors:  Bojan Jelaković; Sandra Karanović; Ivana Vuković-Lela; Frederick Miller; Karen L Edwards; Jovan Nikolić; Karla Tomić; Neda Slade; Branko Brdar; Robert J Turesky; Želimir Stipančić; Damir Dittrich; Arthur P Grollman; Kathleen G Dickman
Journal:  Kidney Int       Date:  2011-11-09       Impact factor: 10.612

Review 2.  Renal organic anion transporters (SLC22 family): expression, regulation, roles in toxicity, and impact on injury and disease.

Authors:  Li Wang; Douglas H Sweet
Journal:  AAPS J       Date:  2012-10-09       Impact factor: 4.009

3.  Effect of base sequence context on the conformational heterogeneity of aristolactam-I adducted DNA: structural and energetic insights into sequence-dependent repair and mutagenicity.

Authors:  Preetleen Kathuria; Purshotam Sharma; Stacey D Wetmore
Journal:  Toxicol Res (Camb)       Date:  2015-10-23       Impact factor: 3.524

4.  Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity.

Authors:  Shih-Yu Chang; Elijah J Weber; Viktoriya S Sidorenko; Alenka Chapron; Catherine K Yeung; Chunying Gao; Qingcheng Mao; Danny Shen; Joanne Wang; Thomas A Rosenquist; Kathleen G Dickman; Thomas Neumann; Arthur P Grollman; Edward J Kelly; Jonathan Himmelfarb; David L Eaton
Journal:  JCI Insight       Date:  2017-11-16

5.  Genetic loci that affect aristolochic acid-induced nephrotoxicity in the mouse.

Authors:  Thomas A Rosenquist
Journal:  Am J Physiol Renal Physiol       Date:  2011-03-23

6.  Aristolochic Acid in the Etiology of Renal Cell Carcinoma.

Authors:  Margaret L Hoang; Chung-Hsin Chen; Pau-Chung Chen; Nicholas J Roberts; Kathleen G Dickman; Byeong Hwa Yun; Robert J Turesky; Yeong-Shiau Pu; Bert Vogelstein; Nickolas Papadopoulos; Arthur P Grollman; Kenneth W Kinzler; Thomas A Rosenquist
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-08-23       Impact factor: 4.254

7.  Sulfotransferase-1A1-dependent bioactivation of aristolochic acid I and N-hydroxyaristolactam I in human cells.

Authors:  Keiji Hashimoto; Irina N Zaitseva; Radha Bonala; Sivaprasad Attaluri; Katherine Ozga; Charles R Iden; Francis Johnson; Masaaki Moriya; Arthur P Grollman; Viktoriya S Sidorenko
Journal:  Carcinogenesis       Date:  2016-04-18       Impact factor: 4.944

Review 8.  p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy.

Authors:  Neda Slade; Ute M Moll; Branko Brdar; Arijana Zorić; Bojan Jelaković
Journal:  Mutat Res       Date:  2009-02-04       Impact factor: 2.433

9.  beta-Naphthoflavone protects mice from aristolochic acid-I-induced acute kidney injury in a CYP1A dependent mechanism.

Authors:  Ying Xiao; Xiang Xue; Yuan-feng Wu; Guo-zheng Xin; Yong Qian; Tian-pei Xie; Li-kun Gong; Jin Ren
Journal:  Acta Pharmacol Sin       Date:  2009-11       Impact factor: 6.150

10.  DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells.

Authors:  Sivaprasad Attaluri; Radha R Bonala; In-Young Yang; Mark A Lukin; Yujing Wen; Arthur P Grollman; Masaaki Moriya; Charles R Iden; Francis Johnson
Journal:  Nucleic Acids Res       Date:  2009-10-23       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.